Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah B Goldberg

Showing results (61-70 of 106) with videos related to

Pageof 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2019
The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung AdenocarcinomaAnna Truini, Jacqueline H Starrett, Tyler Stewart, et al.
JAMA Network Open|August 4, 2022
Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung CancerMatthew D Pichert, Maureen E Canavan, Richard C Maduka, et al.
Journal for Immunotherapy of Cancer|March 14, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapyNaiyer Rizvi, Foluso O Ademuyiwa, Z Alexander Cao, et al.
Journal for Immunotherapy of Cancer|October 21, 2021
Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastasesBenjamin Y Lu, Richa Gupta, Adam Aguirre-Ducler, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 28, 2025
BPI25-017: A Novel Integrated Classification Schema for Molecular Findings by Potential Clinical Actionability: A Tool for Assessment of Real-World Cancer Care in the Targeted Therapy EraXiao Wang, Jessica B Long, John Rothen, et al.
JCO Precision Oncology|June 4, 2025
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line OsimertinibJonathan W Riess, Adrianus J de Langen, Santiago Ponce, et al.
Cancer|March 13, 2016
Patient preferences regarding incidental genomic findings discovered during tumor profilingMelinda L Yushak, Gang Han, Sara Bouberhan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 16, 2026
A Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic ProfilingXiao Wang, Jessica B Long, John Rothen, et al.
Journal of the American Academy of Dermatology|July 21, 2018
Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapyJacob Siegel, Mariam Totonchy, William Damsky, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 31, 2019
Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases AnalysisMyung-Ju Ahn, Chao-Hua Chiu, Ying Cheng, et al.
Pageof 11

Showing results (61-70 of 106) with videos related to

Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2019
The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung AdenocarcinomaAnna Truini, Jacqueline H Starrett, Tyler Stewart, et al.
JAMA Network Open|August 4, 2022
Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung CancerMatthew D Pichert, Maureen E Canavan, Richard C Maduka, et al.
Journal for Immunotherapy of Cancer|March 14, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapyNaiyer Rizvi, Foluso O Ademuyiwa, Z Alexander Cao, et al.
Journal for Immunotherapy of Cancer|October 21, 2021
Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastasesBenjamin Y Lu, Richa Gupta, Adam Aguirre-Ducler, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 28, 2025
BPI25-017: A Novel Integrated Classification Schema for Molecular Findings by Potential Clinical Actionability: A Tool for Assessment of Real-World Cancer Care in the Targeted Therapy EraXiao Wang, Jessica B Long, John Rothen, et al.
JCO Precision Oncology|June 4, 2025
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line OsimertinibJonathan W Riess, Adrianus J de Langen, Santiago Ponce, et al.
Cancer|March 13, 2016
Patient preferences regarding incidental genomic findings discovered during tumor profilingMelinda L Yushak, Gang Han, Sara Bouberhan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 16, 2026
A Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic ProfilingXiao Wang, Jessica B Long, John Rothen, et al.
Journal of the American Academy of Dermatology|July 21, 2018
Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapyJacob Siegel, Mariam Totonchy, William Damsky, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 31, 2019
Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases AnalysisMyung-Ju Ahn, Chao-Hua Chiu, Ying Cheng, et al.
Pageof 11